AstraZeneca today announced that Health Canada has approved
BRILINTA (ticagrelor tablets) for the secondary prevention of atherothrombotic
events in patients with Acute Coronary Syndromes (ACS).

It is estimated that approximately 122,000 Canadians have an
ACS event every year. Data suggests that up to 15 percent of patients with ACS
die within one year of their cardiovascular event .

With the approval in Canada,
BRILINTA has now been approved in 33 countries, including in the European Union
under the trade name BRILIQUE and in Brazil,
Malaysia, and Macau under the trade name BRILINTA. The product is
currently under regulatory review in 42 countries, including the United States, Russia,
India, and China.